Gilead Sciences (GILD) Intangibles (2009 - 2026)
Gilead Sciences (GILD) reported Intangibles of $16.4 billion for Q1 2026, down 15.36% on a YoY basis from $19.4 billion in Q1 2025, and down 3.51% quarter-over-quarter from $17.0 billion in Q4 2025.
Gilead Sciences (GILD) Intangibles (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Intangibles for 18 years, with the latest figure at $16.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Intangibles fell 15.36% year-over-year to $16.4 billion; the trailing twelve-month figure through Mar 2026 stood at $16.4 billion (down 15.36% YoY), and the FY2025 full-year result was $17.0 billion, down 14.89% from the prior year.
- Intangibles for Q1 2026 stood at $16.4 billion, down from $17.0 billion in the prior quarter.
- The five-year high for Intangibles was $30.3 billion in Q1 2022, with the low at $16.4 billion in Q1 2026.
- Historically, Intangibles has averaged $23.8 billion across 5 years, with a median of $23.4 billion in 2024.
- Annual changes were most pronounced in 2023 — Intangibles slipped 6.54% — and 2024, when it dropped 24.59%.
- Gilead Sciences' Intangibles stood at $28.9 billion in 2022, then retreated by 8.44% to $26.5 billion in 2023, then dropped by 24.59% to $19.9 billion in 2024, then declined by 14.89% to $17.0 billion in 2025, then declined by 3.51% to $16.4 billion in 2026.
- The last three Intangibles figures came in at $16.4 billion (Q1 2026), $17.0 billion (Q4 2025), and $18.0 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 24.45 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 7.37 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 49.06 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 50.87 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 18.24 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | 10.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.38 Bn |
| Dec 31, 2025 | 16.98 Bn |
| Sep 30, 2025 | 17.97 Bn |
| Jun 30, 2025 | 18.57 Bn |
| Mar 31, 2025 | 19.36 Bn |
| Dec 31, 2024 | 19.95 Bn |
| Sep 30, 2024 | 20.55 Bn |
| Jun 30, 2024 | 22.83 Bn |
| Mar 31, 2024 | 23.43 Bn |
| Dec 31, 2023 | 26.45 Bn |
| Sep 30, 2023 | 27.15 Bn |
| Jun 30, 2023 | 27.75 Bn |
| Mar 31, 2023 | 28.35 Bn |
| Dec 31, 2022 | 28.89 Bn |
| Sep 30, 2022 | 29.44 Bn |
| Jun 30, 2022 | 29.89 Bn |
| Mar 31, 2022 | 30.33 Bn |
| Dec 31, 2021 | 33.46 Bn |
| Sep 30, 2021 | 33.90 Bn |
| Jun 30, 2021 | 34.34 Bn |